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Summary 
Background: The reliability of diagnostic criteria for invasive fungal diseases (IFD) developed for 
severely immunocompromised patients is questionable in critically-ill adult patients in intensive care 
units (ICU). 
 
Objectives: To develop a standard set of definitions for IFD in critically-ill adult patients in ICU. 
 
Methods: Based on a systematic literature review, a list of potential definitions to be applied to ICU 
patients will be developed by the ESCMID Study Group for Infections in Critically Ill Patients (ESGCIP) 
and the ESCMID Fungal Infection Study Group (EFISG) chairpersons. The proposed definitions will be 
evaluated by a panel of 30 experts using the RAND/UCLA appropriateness methods. The panel will 
rank each of the proposed definitions on a 1-9 scale trough a dedicated questionnaire, in two 
rounds: one remote and one face-to-face. Based on their median rank and the level of agreement 
across panel members, selected definitions will be organized in a main consensus document and in 
an executive summary. The executive summary will be made available online for public comments. 
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Conclusions: The present consensus project will seek to provide standard definitions for IFD in these 
patients, with the ultimate aims of improving their clinical outcome and facilitating the comparison 
and generalizability of research findings. 
 
Key words: Aspergillus; Candida; diagnosis; biomarker; candidiasis; cryptococcosis; pneumocystosis. 
 
Introduction 
Invasive fungal diseases (IFD) are a leading cause of morbidity and mortality in a wide range of 
patients with defects of the immune system or severe underlying organ dysfunction [1-5]. Because 
of the poor sensitivity and/or specificity of some diagnostic tests, the diagnosis of IFD usually relies 
on different degrees of certainty, ranging from possible to proven disease, according to the 2008 
definitions of the European Organization for Research and Treatment of Cancer (EORTC) and the 
Mycoses Study Group (MSG) [6, 7]. These definitions have been originally designed for research 
protocols and their application in clinical practice has been debated, in particular for cases classified 
as possible IFD for which the choice of initiating or refraining from administering antifungal therapy 
may have important consequences and should be assessed on a “case-by-case” approach. Thus, the 
development and use of standard definitions for IFD remain crucial, aiming to reach the most 
favorable, and reproducible net balance between benefits and harms in the intended target 
population. 
The 2008 EORTC-MSG definitions of IFD have been initially designed for immunocompromised 
patients with cancer and hematopoietic stem cell transplant recipients [6, 7]. However, their validity 
for diagnosing IFD in critically ill adult ICU patients not belonging to that target population has been 
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questioned, in view of differences in host factors, disease presentation and performance of 
diagnostic tests in this setting, especially for invasive aspergillosis and intra-abdominal candidiasis 
[11-13]. Possible alternative diagnostic algorithms for ICU patients have been proposed [14-19]. 
We report here the steps we will implement to develop a standard set of definitions for IFD in 
critically ill patients in ICU, starting from a systematic assessment of the strengths and limitations of 
the definitions and algorithms already available in the literature. By publicly declaring our aims, we 
wish to stimulate debate and involve other potentially interested stakeholders as future external 
reviewers of project results. Also, any post-hoc deviations from the protocol, potentially biasing 
results, will be easily tracked and transparently discussed. 
 
Objective and scope 
The objective of the project is to develop a consensus set of definitions for IFD in critically-ill adult 
patients in ICU, with two main goals: (i) to maximize the net balance between benefits and harms 
when diagnosing and treating fungal infections in critically ill adult patients in the daily clinical 
practice; (ii) to provide consistent and reproducible results in research studies on the diagnosis and 
outcome of these infections. 
Definitions will be developed separately for the following IFD: (i) invasive candidiasis (IC); (ii) invasive 
aspergillosis (IA); (iii) Pneumocystis jirovecii pneumonia (PJP); (iv) cryptococcosis; and (v) other rare 
IFD for which a sufficient body of literature is available for developing definitions. 
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Methods 
Participants, roles and task delegation 
A multidisciplinary panel of 30 experts and 5 juniors (DRG, ER, VZ, CG, and FL) has been selected by 
the ESCMID Study Group for Infections in Critically Ill Patients (ESGCIP) and the ESCMID Fungal 
Infection Study Group (EFISG) chairpersons (MB and CLF), based on their experience and expertise in 
the topic or in methodology (Table 1). The panel has been approved by ESGCIP and EFISG for 
ESCMID, and by the executive committee of ESICM, ECCM, and MSGERC. An email invitation was 
sent to all the selected panel members, and all agreed to participate. An external review board 
including patients’ representatives, European Federation of Pharmaceutical Industries and 
Associations (EFPIA) representatives and other stakeholders will be selected and asked to review the 
final document and provide input. The final document will undergo a public consultation phase 
according to ESCMID procedures for endorsement. 
 
Project work packages 
The development of definitions will follow four consecutive stages: (i) identification of relevant 
literature; (ii) drafting of definitions; (iii) consensus development; (iv) public sharing of the consensus 
executive summary. 
Coordination will be provided by MB and TC. The entire project will be managed remotely, with only 
one face-to-face meeting expected during the 29th European Congress of Clinical Microbiology and 
Infectious Diseases (ECCMID, 13-16 April 2019, Amsterdam, Netherlands). 
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WP1: Identification of relevant literature 
A systematic review will be conducted (CR) to identify all the definitions for IFD available in the 
literature, without restriction to ICU patients. We expect most definitions will have been developed 
for other-than-ICU settings. The expert panel’s role will be to judge the applicability of definitions 
developed in other settings to ICU patients, and to determine if modifications are needed. 
 
Eligibility criteria for full text inclusion: 
 Study design: cross sectional studies, longitudinal (cohort) prospective or retrospective 
studies, randomized controlled trials, single-arm studies, quasi-experimental studies (case 
series and case-control studies will be excluded) 
 Patient populations: all 
 Patient’s age: adult patients (explicitly defined as ≥18 years) 
 Settings: all 
 IFD of interest: IC, IA, PJP, cryptococcosis, other 
 Explicit definition of the IFD of interest 
  
Sources and limits/restrictions 
We will search the MEDLINE and EMBASE (OvidSP), CINAHL (EBSCOHost), and the Cochrane 
Database (Wiley). We will use medical subject headings (MeSH) and terms for IFD (e.g., aspergillosis, 
candidiasis) and definitions. The search period will be from 2003 to 2018 (15 years). No language 
restrictions will be applied. 
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Data management 
All abstract and full text will be imported and managed into an EndNotesWeb database, shared 
among the 5 Juniors and librarian. 
 
Selection process 
According to the IFD of interest, five search strings will be built and four reviewers (DRG, FL, VZ and 
CG) will perform abstract screenings and full-text review. The reviewers will work in pairs and each 
pair will be in charge of 2/3 topics: IC and PJP for DRG and VZ while IA, cryptococcosis, and other IFD 
for FL and CG. The reference lists of retrieved full-texts will also be screened, to identify further 
papers suitable for inclusion. The two members of each pair will work independently; decisions will 
be compared and any possible disagreement will be resolved by a fifth independent reviewer (ER). 
 
Data extraction 
Data will be extracted on a standard extraction form; the form will be drafted by VZ, and piloted by 
DRG, ER, and FL on a subset of 2 full-text each. This stage will be supervised by LS. For all data items, 
both a descriptive field for verbatim data extraction and a categorical field with a limited number of 
mutually exclusive classification options will be used. 
Data extraction will be performed analogously to the selection process. 
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Data items 
Each definition will be summarized descriptively or (whenever applicable) quantitatively according 
to: 
 target IFD/s 
 target population/s 
 number of diagnostic categories (e.g. positive/negative vs positive/indeterminate/negative 
vs proven/probable/possible/excluded) 
 number of patients enrolled 
 reference standard applied 
 diagnostic performance (sensitivity, specificity, negative predictive value, positive predictive 
value, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio whenever 
an appropriate diagnostic gold standard is available; repeatability and reproducibility in 
absence of an appropriate diagnostic gold standard) 
 need for microbiological/biochemical testing, including costs 
 strengths and limitations, overall and with regard to the applicability to critically ill patients 
in ICU 
 clinical outcomes used for validation (including net balance between benefits and harms), if 
any  
 risk of bias of studies (see later). 
Each of the 30 experts of the panels will be asked to provide comments and to critically review the 
results and the summary of the systematic review. 
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Risk of bias of included studies 
The risk of bias of included studies will be assessed by a simple scoring system specifically designed 
for this project: 1 point for each of the following: 
1) retrospective study 
2) missing IFD classification of >10% of included patients (for loss of follow-up or other reasons) 
3) developed in populations other than ICU  
4) exclusion of patients difficult to diagnose from the study 
5) combination of adults and children 
6) ad hoc selection of the cut-off value (where applicable) 
7) unreliability of the reference standard (according to expert judgement) 
8) Classification as IFD after knowledge of the result of the reference standard   
Higher total scores will therefore correspond to higher risk of bias. 
 
Data synthesis 
No attempt at formal data synthesis is applicable to our aims (see WP2). 
 
WP2: Drafting of IFD definitions 
On the basis of the results of the literature review, chairperson of ESGCIP (MB) and EFISG (CLF), will 
draw a list of potential definitions or diagnostic strategies for each IFD (aspergillosis, candidiasis, PJP, 
cryptococcosis, and other IFD) in critically-ill adult patients in ICU. According to the degree of 
certainty of mycological diagnosis and the level of scientific rigor if adopted in research studies, the 
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project coordinators (MB and TC) will also categorize IFD, within each definition, as follows : (i) 
possible IFD; (ii) probable IFD; (iii) proven IFD. For each IFD, definitions will not need to be mutually 
exclusive, since they will be scored individually. The list will be organized in a questionnaire format 
to be answered by all panel members, as described below. 
 
WP3: Consensus development 
With the results of the systematic review provided as background information to the selected 30 
experts, the proposed definitions will be evaluated using the RAND/UCLA appropriateness methods 
(RAND/UCLA) [20]. In a first phase, mail invitations to participate in the questionnaire will be sent to 
the 30 experts. Responses will be collected using the REDCapTM software [21]. The experts will be 
asked to rank each of the proposed definitions on a 1-9 scale, with 1 indicating that the expected 
harms of adopting the proposed definition in ICU patients considerably outweigh the expected 
benefits (i.e. not appropriate) , and 9 conversely indicating that the expected benefits outweigh the 
expected harms (i.e. always appropriate). In this regard, experts will be instructed that the expected 
benefits in the context of disease definitions might involve increased access to treatment with 
beneficial effects on both health and non-health outcomes, while expected harms might involve 
physical harms of diagnosis and treatment, psychological effects, and social and economic 
consequences [10]. The median score will be used to classify each definition as inappropriate (1-3), 
“definition that might be considered” (4-6), “appropriate definition” (7-9). Experts will also be given 
the opportunity to provide additional potential definitions to be evaluated by the panel, that will be 
assessed in another round of rating trough the REDCapTM software. Additional rounds will be 
conducted until no new proposals of definition are added by the experts during the rating process. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
In a second phase, the 30 experts will be involved in a face-to-face meeting during the 29th European 
Congress of Clinical Microbiology and Infectious Diseases (ECCMID, 13-16 April 2019, Amsterdam, 
Netherlands), in which the results of the online questionnaire will be made available to each 
individual member of the panel. Only definitions “that might be considered” and “appropriate” will 
be discussed. Chaired by a facilitator (LS), the 30 experts will discuss each of the rated definitions, as 
well as their categorization, and finally vote anonymously as to whether adopt or reject each 
definition. Consensus will be defined as ≥ 70% agreement towards acceptance, with <15% 
disagreeing. The process will be repeated until consensus is reached. As a final step, if contradictory 
definitions for the same etiological pathogen will be present in the same category (possible, 
probable, or proven), experts will discuss and vote anonymously on which one should be retained, 
with only the one receiving more votes being ultimately included in the consensus document. 
 
WP4: Public sharing of the consensus executive summary 
The project will be presented through a slide set presentation during the 29th European Congress of 
Clinical Microbiology and Infectious Diseases (ECCMID, 13-16 April 2019, Amsterdam, Netherlands), 
and where the public consultation phase will be duly advertised. The public consultation phase will 
be performed remotely by means of email exchanges and email Delphi rounds to respond to 
comments. Formal approval by all experts will be required prior to submission for publication. 
The selected definitions and the background information for each of them (i.e., results of the 
systematic reviews and experts’ comments) will be organized in a main consensus document and in 
an executive summary.  
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Publication 
The ICMJE criteria for authorship will apply. The first author will draft the manuscript and coordinate 
input from all other authors; the last author will be guarantor. Three members from each Society will 
be in the authors byline with their full name. 
Authorship byline will include the study group name, and a table with all the FUNDICU study group 
names will be included in the manuscript (each member will qualify as author). 
Timeline 
All activities are expected to cover a 14 months period (Figure 1). 
Discussion 
Existing guidance on how to properly diagnose IFD in critically ill adult patients in ICU is still limited. 
Most IFD definitions are aimed at severely immunocompromised patients. However, most often 
those definitions do not apply to ICU patients, who usually show considerable differences with the 
populations mentioned above in terms of risk factors and performances of various diagnostic 
procedures.  
The impact of such differences could be somewhat elusive at first glance, but for this very reason 
they may considerably bias clinical reasoning, as well as the way we interpret research results. For 
example, sensitivity and specificity both of galactomannan and of the 2008 EORTC/MSG definition of 
probable IA may be very different between hematology patients and non-immunocompromised 
patients with severe COPD in the ICU [15-17]. As a consequence, interpreting and weighing  
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possibility and probability of IFD in the same way we do it in hematology patients might not always 
lead to the most cost-effective choice in the ICU, for several reasons. First, what is probable in 
hematology may just be possible in the ICU, or vice versa, since lesions and symptoms of IFD in ICU 
are often different from those developing in hematology patients, and they also present with a 
different spectrum of potential alternative diagnoses. Second, there may be more heterogenous 
levels of urgency in the ICU than in hematology patients, and a slight delay in prompting empirical 
treatment in favor of further diagnostics might be preferable in some selected cases. Third, specific 
ICU-related risk factors and tests performances should be considered and weighed carefully when 
categorizing the risk of some IFD such as candidemia, in order not to put some truly candidemic 
patients at risk of delayed antifungal therapy and reduced survival [22,23].  
Classifying ICU patients according to their specific likelihood of having an IFD is therefore extremely 
important to properly guide and maximize the benefits of diagnostic and treatment decisions, in 
order to reduce both overtreatment and undertreatment. This is also intimately connected with our 
ability to conduct good clinical research on IFD in ICU. For example, overtreatment due to lack of 
appropriate diagnostics also reduces the reliability of epidemiological studies on the incidence and 
prevalence of probable/proven IFD in the ICU, because of possible missed episodes (randomly or 
systematically). Misclassification might also influence other types of observational and 
investigational research, since IFD can also be the outcome of clinical trials of preventive strategies, 
or of diagnostic studies of new lab or radiology tests. Furthermore, they can also represent the 
patient population (the “P” of the PICO acronym) in treatment studies. 
The development of standard definitions of IFD in ICU patients is in line with the Measures in 
Effectiveness Trials (COMET) initiative, which supports development and application of “core 
outcome sets” (COS) [25]. A COS is an “agreed standardised set of outcomes representing the 
minimum that should be measured and reported in all clinical trials of a specific condition”. In this 
regard, standardization would make it easier for the results of clinical studies to be compared, 
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contrasted and combined as appropriate in systematic reviews and meta-analyses, thus reducing 
“waste” in information and in resources [25,26].  
The rigorous and systematic interpretation of the current literature is also the basis of the present 
consensus development project; on the other hand, among the potential limitations of our initiative, 
we acknowledge the possible limited availability of good quality literature for some definitions, and 
the possible lack of ICU-dedicated studies for certain IFD and laboratory or radiological tests. 
We welcome comments and expressions of interest for participation to the external review group 
(please address any correspondence to the corresponding author). 
We ultimately hope these definitions will help to improve the outcome of IFD in ICU patients, as well 
as to facilitate the comparison and generalizability of research findings. 
Ethics and consent 
The protocol does not involve patients and does not require approval by Ethical Review Board. It has 
been extensively reviewed from the scientific point of view. 
The protocol for the systematic review component will be registered at the PROSPERO database. 
Funding 
The present project will not require additional funding from routine research activities. Costs for 
open access publications will be covered by research funds of the main authors. 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Conflicts of interest (CoI) 
CoI declarations will be collected at the beginning and at the end of the project (with mandatory 
update in case of intervening new CoI) and reviewed by an independent panel. The ICMJE form will 
be adopted. 
 
Availability of data and material 
Not applicable to the current protocol. 
 
Authors’ contribution 
Authors’ contributions are detailed in Table 1. 
 
 
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 1: FUNGICU project participants 
Name Institution Role Tasks 
Matteo Bassetti Infectious Diseases 
Division, Santa Maria 
Misericordia Hospital, 
Udine, Italy 
Principal investigator, 
ESGCIP chair, expert 
panel member 
Coordination, first 
drafting  of IFD 
definitions after 
systematic review, 
development of IFD 
definitions and 
consensus document 
(RAND/UCLA method)  
Thierry Calandra Infectious Diseases 
Service, Department of 
Medicine, Lausanne 
University, Lausanne, 
Switzerland 
Co-Principal 
investigator, expert 
panel member 
Coordination, 
development of IFD 
definitions and 
consensus document 
(RAND/UCLA method) 
Cornelia Lass-Flörl Division of Hygiene and 
Medical Microbiology, 
Medical University 
Innsbruck, Innsbruck, 
Austria. 
EFISG chair, expert 
panel member 
first drafting  of IFD 
definitions after 
systematic review, 
development of IFD 
definitions and 
consensus document 
(RAND/UCLA method) 
Luigia Scudeller IRCCS Policlinic San 
Matteo, Pavia, Italy 
Methodology 
supervision 
Protocol development, 
supervision of 
systematic review, 
facilitation of face-to-
face meeting/s 
Daniele R. Giacobbe Clinica Malattie 
Infettive, Ospedale 
Policlinico San Martino 
– IRCCS per l’Oncologia, 
Genoa, Italy 
Methodology, junior 
panel member 
Protocol development, 
systematic review, 
drafting of consensus 
document 
Frederic Lamoth Infectious Diseases 
Service, Department of 
Medicine, Lausanne 
University, Lausanne, 
Switzerland, and 
Institute of 
Microbiology, Lausanne 
University Hospital, 
Lausanne, Switzerland 
Methodology, junior 
panel member 
Protocol development, 
systematic review, 
drafting of consensus 
document 
Elda Righi Infectious Diseases 
Division , Santa Maria 
Misericordia Hospital , 
Udine , Italy 
Methodology, junior 
panel member 
Protocol development. 
Systematic review, 
drafting of consensus 
document 
Valentina Zuccaro IRCCS Policlinic San 
Matteo, Pavia, Italy 
Methodology, junior 
panel member 
Protocol development. 
Systematic review 
Cecilia Grecchi IRCCS Policlinic San 
Matteo, Pavia, Italy 
Methodology, junior 
panel member 
Protocol development. 
Systematic review 
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Chiara Rebuffi IRCCS Policlinic San 
Matteo, Pavia, Italy 
Expert medical 
librarian 
Protocol development. 
Systematic review 
Murat Akova 
 
Department of 
Infectious Diseases and 
Clinical Microbiology, 
Faculty of Medicine, 
Hacettepe University 
Ankara, Turkey 
Expert panel member Development of IFD 
definitions and 
consensus document 
(RAND/UCLA method) 
Ana Alastruey-
Izquierdo 
 
Spanish Center for 
Microbiology, Instituto 
de Salud Carlos III, 
Madrid, Spain 
Expert panel member Development of IFD 
definitions and 
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Figure legends 
Figure 1. Study timeline. 
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